American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 830-833 , November 2008

Breast Cancer Screening and Dialysis: Too Much or Too Little

  • Idris Guessous, MD

      Affiliations

    • Emory University, Atlanta, Georgia
    • ,
  • Valerie Duhn, MD

      Affiliations

    • Emory University School of Medicine, Atlanta, Georgia
    • ,
  • William McClellan, MD, MPH

      Affiliations

    • Emory University, Emory University School of Medicine, Atlanta, Georgia
    • Corresponding Author InformationAddress correspondence to William McClellan, MD, MPH, Rollins School of Public Health, Emory University, 1518 Clifton Rd, Atlanta, GA 30322

References 

  1. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005 [based on November 2007 SEER data submission]. Bethesda, MD, National Cancer Institute http://seer.cancer.gov/csr/1975_2005/Accessed September 15, 2008
  2. National Guideline Clearinghouse: Guideline Synthesis: Screening for Breast Cancer (revised June 2008). http://www.guideline.govAccessed July 25, 2008
  3. Chertow GM, Paltiel AD, Owen WF, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med. 1996;156:1345–1350
  4. LeBrun CJ, Diehl LF, Abbott KC, Welch PG, Yuan CM. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis. 2000;35:237–243
  5. Kajbaf S, Nichol G, Zimmerman D. Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant. 2002;17:1786–1789
  6. Wong G, Howard K, Chapman JR, Craig JC. Cost-effectiveness of breast cancer screening in women on dialysis. Am J Kidney Dis. 2008;52:916–929
  7. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line. In:  Sloan FA editors. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press; 1995;
  8. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis. 1989;14:119–123
  9. Teschner M, Garte C, Rückle-Lanz H, et al. Incidence and spectrum of malignant disease among dialysis patients in North Bavaria. Dtsch Med Wochenschr. 2002;127:2497–2502
  10. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93–99
  11. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347–360
  12. Greenland D, Rothman KJ. Measures of occurrence. In:  Rothman KJ,  Greenland S,  Lash TL editor. Modern epidemiology. (ed 3). Baltimore, MD: Lippincott Williams & Wilkins; 2008;chap 3
  13. Racki S, Zaputović L, Vujicić B, Crncević-Orlić Z, Dvornik S, Mavrić Z. Comparison of survival between diabetic and non-diabetic patients on maintenance hemodialysis: a single-centre experience. Diabetes Res Clin Pract. 2007;75:169–175
  14. Walter LC, Lindquist K, O'Hare AM, Johansen KL. Targeting screening mammography according to life expectancy among women undergoing dialysis. Arch Intern Med. 2006;166:1203–1208
  15. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148:337–347
  16. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204–1214
  17. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93:358–366
  18. Castellanos M, Varma S, Ahern K, et al. Increased breast calcifications in women with ESRD on dialysis: Implications for breast cancer screening. Am J Kidney Dis. 2006;48:301–306
  19. Castellanos MR, Paramanathan K, El-Sayegh S, Forte F, Buchbinder S, Kleiner M. Breast cancer screening in women with chronic kidney disease: The unrecognized effects of metastatic soft-tissue calcification. Nat Clin Pract. 2008;4:337–341
  20. Davison SN, Holley JL. Ethical issues in the care of vulnerable chronic kidney disease patients: the elderly, cognitively impaired, and those from different cultural backgrounds. Adv Chronic Kidney Dis. 2008;15:177–185
  21. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine (Panel on Cost-Effectiveness in Health and Medicine). JAMA. 1996;276:1172–1177
  22. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst. 1993;85:1460–1474
  23. Wagner JL. Cost-effectiveness of screening for common cancers. Cancer Metastasis Rev. 1997;16:281–294
  24. Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol. 2007;25:203–208

PII: S0272-6386(08)01357-7

doi: 10.1053/j.ajkd.2008.09.007

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 830-833 , November 2008

Article Tools